Revised forecast
Fiscal year ending March 2026 · Full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document.
Reversal of the US$86 million upfront contract payment received in the previous fiscal year under the intellectual property transfer and sales partnership option agreement for NM26, and the US$30 million upfront contract payment under the license agreement for the STAT6 inhibitor. In addition, domestic pharmaceutical sales declined, particularly as the shift to AGs for the core product group CreNAfin progressed from September 2025 onward.
| Item | Details |
|---|---|
| Net Sales | △21,620 |
| Operating profit | △23,217 |
| Ordinary income | △22,879 |
| Profit attributable to owners of the parent | △14,484 |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Period Covered | Full year |
| Previous-period results | Net sales: ¥93,934 million; operating profit: ¥22,522 million; ordinary profit: ¥22,766 million; net income: ¥16,449 million; net income per share: ¥431.06 |
| Reason for the revision | Reversal of the US$86 million upfront contract payment received in the previous fiscal year under the intellectual property transfer and sales partnership option agreement for NM26, and the US$30 million upfront contract payment under the license agreement for the STAT6 inhibitor. In addition, domestic pharmaceutical sales declined, particularly as the shift to AGs for the core product group CreNAfin progressed from September 2025 onward. |
| Consolidated / non-consolidated | Non-consolidated |
Items this document does not state (4)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In addition to the reversal of the US$86 million upfront contract payment for NM26 and the US$30 million upfront contract payment for the STAT6 inhibitor received in the previous fiscal year, domestic pharmaceutical sales declined, particularly as the shift to authorized generics (AGs) for the core product group CreNAfin progressed from September 2025 onward.